Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2000

View Archived Issues

Purpurinimide photosensitizers with in vivo tumoricidal effects

Medarex and IDM expand partnership, announce phase III trial

Melatonin aids in benzodiazepine discontinuation

Athersys and Elan form joint venture to develop therapeutic protein for AIDS

Estrogenic activities described for 7alpha-thioestratrienes

Strategic collaboration formed by 3-D and DuPont

Sonus and Abbott amend EchoGen marketing agreement

Cel-Sci updates shareholders on progress during 1999

Solvay launches three products in 1999

Promising new atherosclerosis treatment expected to enter clinical trials later this year

Topical tazarotene effective in congenital ichthyosis

International collaboration to create HIV vaccine for developing countries

Metabolex outlines company's goals at BIO CEO and Investor Conference

Alza outlines growth strategy at annual financial analysts meeting

Novartis executes option for oral salmon calcitonin

Isis Pharmaceuticals makes important progress on many fronts in 1999

European patent describes preparation and activity of new erythromycin antibiotics

New series of taxanes designed at BMS

AstraZeneca portfolio includes new series of P2T antagonists

New prostate cancer therapy to be studied in men with no other effective treatment options

UCSD researchers report fundamental breakthrough in treating, preventing shock

Agents for HCV under study at Ajinomoto

Polyhydroxyalkylpyrazine derivatives for diabetes synthesized at Aventis

Pierre Fabre designs structurally novel inhibitors of protein prenylation

Potent and selective alpha1D-adrenoceptor antagonists presented by Abbott

FDA approves first vaccine for prevention of invasive pneumococcal disease in infants and toddlers

Adenosine A1 antagonists as alternatives to diuretics in CHF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...